Best of ASCO - 2014 Annual Meeting

 

Welcome

Attend this session at the
2017 ASCO Annual Meeting!


Session: Gastrointestinal (Colorectal) Cancer

Type: Poster Session

Time: Saturday June 3, 8:00 AM to 11:30 AM

Location: Hall A


Session: Gastrointestinal (Colorectal) Cancer

Type: Poster Discussion Session

Time: Saturday June 3, 1:15 PM to 2:30 PM

Location: Arie Crown Theater

Nut consumption and survival in stage III colon cancer patients: Results from CALGB 89803 (Alliance).

Sub-category:
Biomarkers/Epidemiology/Outcomes

Category:
Gastrointestinal (Colorectal) Cancer

Meeting:
2017 ASCO Annual Meeting

Abstract No:
3517

Poster Board Number:
Poster Discussion Session (Board #140)

Citation:
J Clin Oncol 35, 2017 (suppl; abstr 3517)

Author(s): Temidayo Fadelu, Donna Niedzwiecki, Sui Zhang, Xing Ye, Leonard Saltz, Robert J. Mayer, Rex B. Mowat, Renaud Whittom, Alexander Hantel, Al Bowen Benson, Daniel M. Atienza, Michael J. Messino, Hedy L. Kindler, Alan P. Venook, Shuji Ogino, Kimmie Ng, Edward L. Giovannucci, Jeffrey A. Meyerhardt, Ying Bao, Charles S. Fuchs; Dana-Farber Cancer Institute, Boston, MA; Alliance Statistics and Data Center, Durham, NC; Dana-Farber Cancer Institute/Partners CancerCare, Boston, MA; Duke University, Durham, NC; Memorial Sloan-Kettering Cancer Center, New York, NY; Toledo Clinic, Toledo, OH; Hospital Sacre-Coeur de Montreal, Montreal, QC, Canada; Edward Cancer Center, Naperville, IL; Northwestern University, Chicago, IL; Virginia Oncology Associates, Suffolk, VA; Cancer Care of WNC PA, Asheville, NC; University of Chicago, Chicago, IL; University of California, San Francisco, San Francisco, CA; Brigham and Women's Hospital, Boston, MA; Harvard T.H. Chan School of Public Health, Harvard Medical School, Brigham and Women's Hospital, Boston, MA; Channing Division of Network Medicine, Boston, MA

Abstract Disclosures

Abstract:

Background: Recent prospective cohort studies suggest states of energy excess and hyperinsulinemia, including type 2 diabetes (T2D), obesity, sedentary lifestyle, Western pattern diet, increased dietary glycemic load, high intake of sugar-sweetened beverages, and elevated plasma C-peptide are each associated with an increased risk of colon cancer (CC) recurrence and mortality. Conversely, observational studies indicate that increasing nut intake is associated with lower risk of T2D, metabolic syndrome and insulin resistance. However, the effect of nut intake on CC recurrence and survival is unknown. Methods: We conducted a prospective, observational study of 826 patients with stage III CC who reported dietary intake with food frequency questionnaires while enrolled in a randomized adjuvant chemotherapy trial. Using Cox proportional hazards regression, we assessed associations of nut intake with cancer recurrence and mortality. The primary endpoint was disease-free survival (DFS) defined as time from completion of dietary questionnaire following adjuvant therapy to cancer recurrence, death or last follow-up. Results: Compared to patients who abstained from nuts, those who consumed ≥ 2 servings of nuts per week had an adjusted hazard ratio (HR) of 0.58 (95% CI, 0.37 to 0.92; Ptrend = 0.03) for DFS and 0.43 (95% CI, 0.25 to 0.74; Ptrend = 0.01) for overall survival (OS). On subgroup analysis, the significant association was confined to tree-nut intake: HR = 0.54 (95% CI, 0.34 to 0.85; Ptrend = 0.04) for DFS and HR = 0.47 (95% CI, 0.27 to 0.82; Ptrend= 0.04) for OS. There was no significant association between intake of peanut or peanut butter and patient outcome. Association of total nut intake with improved outcomes was maintained across other known or suspected predictors of recurrence and mortality, including across common genomic alterations (microsatellite instability, KRAS mutation, BRAF mutation, and PIK3CA mutation). Conclusions: Higher consumption of nuts may be associated with significantly reduced cancer recurrence and death in patients with stage III CC. Support: U10CA180821, U10CA180882, Pfizer. Clinical trial information: NCT00003835

 
Other Abstracts in this Sub-Category:

 

1. Clinical utility of colon cancer molecular subtypes: Validation of two main colorectal molecular classifications on the PETACC-8 phase III trial cohort.

Meeting: 2017 ASCO Annual Meeting Abstract No: 3509 First Author: Laetitia Marisa
Category: Gastrointestinal (Colorectal) Cancer - Biomarkers/Epidemiology/Outcomes

 

2. Analysis of serum vitamin D levels and prognosis in stage III colon carcinoma patients treated with adjuvant FOLFOX+/- cetuximab chemotherapy: NCCTG N0147 (Alliance).

Meeting: 2017 ASCO Annual Meeting Abstract No: 3516 First Author: Frank A. Sinicrope
Category: Gastrointestinal (Colorectal) Cancer - Biomarkers/Epidemiology/Outcomes

 

3. The potential of circulating tumor DNA (ctDNA) to guide adjuvant chemotherapy decision making in locally advanced rectal cancer (LARC).

Meeting: 2017 ASCO Annual Meeting Abstract No: 3521 First Author: Jeanne Tie
Category: Gastrointestinal (Colorectal) Cancer - Biomarkers/Epidemiology/Outcomes

 

More...